7 years of historical data (2019–2025) · Healthcare · Medical - Instruments & Supplies
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Bausch + Lomb Corporation currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $5.3B | $6.0B | $6.4B | $6.0B | $5.4B | — | — | — |
| Enterprise Value | $10.3B | $11.0B | $11.0B | $10.3B | $7.6B | — | — | — |
| P/E Ratio → | -14.58 | — | — | — | 361.54 | — | — | — |
| P/S Ratio | 1.04 | 1.18 | 1.33 | 1.44 | 1.44 | — | — | — |
| P/B Ratio | 0.81 | 0.93 | 0.97 | 0.86 | 0.76 | — | — | — |
| P/FCF | — | — | — | — | 31.93 | — | — | — |
| P/OCF | 18.73 | 21.35 | 27.39 | — | 15.73 | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
Bausch + Lomb Corporation's enterprise value stands at 16.9x EBITDA, roughly in line with its 5-year average of 17.4x. The Healthcare sector median is 14.2x, placing the stock at a 19% premium on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.16 | 2.29 | 2.49 | 2.02 | — | — | — |
| EV / EBITDA | 16.89 | 18.11 | 18.37 | 20.16 | 12.97 | — | — | — |
| EV / EBIT | 54.73 | 58.67 | 66.57 | 88.22 | 34.71 | — | — | — |
| EV / FCF | — | — | — | — | 44.72 | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Bausch + Lomb Corporation earns an operating margin of 3.7%. A negative ROE of -5.5% indicates the company is currently destroying shareholder equity. ROIC of 1.2% represents below-average returns on invested capital.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 54.8% | 54.8% | 60.9% | 60.4% | 59.7% | 61.0% | 62.3% | 64.9% |
| Operating Margin | 3.7% | 3.7% | 3.4% | 3.1% | 5.5% | 8.7% | 7.6% | 10.5% |
| Net Profit Margin | -7.1% | -7.1% | -6.6% | -6.3% | 0.2% | 4.8% | -0.5% | 7.9% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -5.5% | -5.5% | -4.7% | -3.7% | 0.1% | 1.9% | -0.2% | 3.0% |
| ROA | -2.6% | -2.6% | -2.4% | -2.1% | 0.1% | 1.6% | -0.2% | 2.6% |
| ROIC | 1.2% | 1.2% | 1.1% | 0.9% | 1.7% | 2.6% | 2.0% | 3.0% |
| ROCE | 1.6% | 1.6% | 1.4% | 1.2% | 2.1% | 3.3% | 2.5% | 3.8% |
Solvency and debt-coverage ratios — lower is generally safer
Bausch + Lomb Corporation carries a Debt/EBITDA ratio of 8.8x, which is highly leveraged (174% above the sector average of 3.2x). Net debt stands at $5.0B ($5.4B total debt minus $383M cash). Interest coverage of just 0.4x is concerning — the company has limited headroom to absorb earnings volatility before struggling with debt service.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.82 | 0.82 | 0.75 | 0.68 | 0.36 | 0.01 | 0.01 | 0.01 |
| Debt / EBITDA | 8.82 | 8.82 | 8.25 | 9.13 | 4.36 | 0.19 | 0.14 | 0.11 |
| Net Debt / Equity | — | 0.76 | 0.71 | 0.63 | 0.31 | -0.00 | -0.01 | -0.01 |
| Net Debt / EBITDA | 8.19 | 8.19 | 7.74 | 8.48 | 3.71 | -0.05 | -0.20 | -0.11 |
| Debt / FCF | — | — | — | — | 12.79 | -0.05 | -0.52 | -0.16 |
| Interest Coverage | 0.44 | 0.44 | 0.41 | 0.41 | 1.50 | — | — | — |
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.55x means Bausch + Lomb Corporation can comfortably meet its short-term obligations, though there is limited excess liquidity. The quick ratio of 1.04x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has declined from 1.74x to 1.55x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.55 | 1.55 | 1.60 | 1.74 | 1.65 | 1.49 | 1.82 | 1.64 |
| Quick Ratio | 1.04 | 1.04 | 1.01 | 1.09 | 1.16 | 0.97 | 1.14 | 1.07 |
| Cash Ratio | 0.20 | 0.20 | 0.18 | 0.21 | 0.29 | 0.16 | 0.26 | 0.19 |
| Asset Turnover | — | 0.36 | 0.36 | 0.31 | 0.34 | 0.35 | 0.30 | 0.33 |
| Inventory Turnover | 2.36 | 2.36 | 1.81 | 1.60 | 2.42 | 2.56 | 2.09 | 2.24 |
| Days Sales Outstanding | — | 87.37 | 78.17 | 77.03 | 70.33 | 69.90 | 69.00 | 68.88 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Bausch + Lomb Corporation does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | 0.3% | — | — | — |
| FCF Yield | — | — | — | — | 3.1% | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.2% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.2% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $354M | $352M | $351M | $350M | $350M | $350M | $350M |
Compare BLCO with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| $5B | -14.6 | 16.9 | — | 54.8% | 3.7% | -5.5% | 1.2% | 8.8 | |
| $9B | 24.4 | 11.9 | 16.0 | 29.1% | 5.7% | 8.3% | 7.1% | 3.4 | |
| $1B | -120.0 | 80.7 | 30.2 | 74.4% | -0.6% | -2.4% | -0.6% | 5.2 | |
| $7B | 30.5 | 16.8 | 19.1 | 61.1% | 20.2% | 21.4% | 30.6% | 0.0 | |
| $550B | 39.4 | 19.1 | 27.7 | 69.1% | 24.9% | 20.1% | 20.7% | 1.2 | |
| $154B | 11.6 | 16.1 | 24.2 | 50.8% | 16.3% | 30.9% | 9.9% | 1.5 | |
| $13B | 35.2 | 14.0 | 29.6 | 60.7% | 16.7% | 4.6% | 4.8% | 2.5 | |
| $17B | 30.5 | 17.4 | 18.4 | 61.0% | 17.4% | 11.1% | 9.4% | 2.6 | |
| $1B | -2.6 | 14.4 | — | 51.7% | 4.2% | -39.9% | 1.7% | 9.3 | |
| $13B | 32.2 | 15.2 | 26.6 | 68.3% | 15.3% | 10.4% | 15.4% | 0.1 | |
| $2B | 11.1 | 6.3 | 1.8 | 60.9% | 21.3% | 588.2% | 8.2% | 6.1 | |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Includes 30+ ratios · 7 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying BLCO stock.
Bausch + Lomb Corporation's current P/E ratio is -14.6x. This places it at the 50th percentile of its historical range.
Bausch + Lomb Corporation's current EV/EBITDA is 16.9x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 17.4x.
Bausch + Lomb Corporation's return on equity (ROE) is -5.5%. The historical average is -1.3%.
Based on historical data, Bausch + Lomb Corporation is trading at a P/E of -14.6x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Bausch + Lomb Corporation has 54.8% gross margin and 3.7% operating margin.
Bausch + Lomb Corporation's Debt/EBITDA ratio is 8.8x, indicating high leverage. A ratio above 4x may signal elevated financial risk.